Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 316

Results For "pharma"

4743 News Found

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData
News | September 03, 2023

BioNTech to lead $2 billion mRNA-based oncology therapy market despite challenges, says GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials


Sanofi announces changes to its Executive Committee
People | September 01, 2023

Sanofi announces changes to its Executive Committee

Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.


Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension
Drug Approval | August 31, 2023

Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension

The approval bolsters the company's Mycophenolate Mofetil portfolio


Lupin receives USFDA approval for Pirfenidone Capsules
Drug Approval | August 31, 2023

Lupin receives USFDA approval for Pirfenidone Capsules

Pirfenidone Capsules had estimated annual sales of USD 95 million in the US


Unichem receives ANDA approval for Prasugrel Tablets
Drug Approval | August 31, 2023

Unichem receives ANDA approval for Prasugrel Tablets

Prasugrel tablets are indicated to reduce the rate of thrombotic CV events


Lupin launches propranolol capsules to improve heart health in Canada
News | August 31, 2023

Lupin launches propranolol capsules to improve heart health in Canada

Propranolol LA is a generic equivalent of Inderal LA


Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales
News | August 30, 2023

Novo Nordisk, Eli Lilly record growth in Q2 driven by obesity, diabetes drug sales

Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion


BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
Clinical Trials | August 29, 2023

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year


Briefs: Granules India
Drug Approval | August 28, 2023

Briefs: Granules India

Granules India received approval from Brazilian Health Regulatory Agency ANVISA